PT1770162E - Composições imunológicas para a modulação da miostatina em indivíduos vertebrados - Google Patents

Composições imunológicas para a modulação da miostatina em indivíduos vertebrados Download PDF

Info

Publication number
PT1770162E
PT1770162E PT06026306T PT06026306T PT1770162E PT 1770162 E PT1770162 E PT 1770162E PT 06026306 T PT06026306 T PT 06026306T PT 06026306 T PT06026306 T PT 06026306T PT 1770162 E PT1770162 E PT 1770162E
Authority
PT
Portugal
Prior art keywords
immunological compositions
vertebrate subjects
modulate myostatin
myostatin
modulate
Prior art date
Application number
PT06026306T
Other languages
English (en)
Inventor
Christopher A Barker
Mohamad Morsey
Original Assignee
Metamorphix International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metamorphix International Inc filed Critical Metamorphix International Inc
Publication of PT1770162E publication Critical patent/PT1770162E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT06026306T 1998-02-19 1999-02-19 Composições imunológicas para a modulação da miostatina em indivíduos vertebrados PT1770162E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7521398P 1998-02-19 1998-02-19

Publications (1)

Publication Number Publication Date
PT1770162E true PT1770162E (pt) 2009-03-24

Family

ID=22124285

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99904660T PT1056845E (pt) 1998-02-19 1999-02-19 Composições imunologicas para modular a miostatina em vertebrados
PT06026306T PT1770162E (pt) 1998-02-19 1999-02-19 Composições imunológicas para a modulação da miostatina em indivíduos vertebrados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT99904660T PT1056845E (pt) 1998-02-19 1999-02-19 Composições imunologicas para modular a miostatina em vertebrados

Country Status (18)

Country Link
US (2) US6369201B1 (pt)
EP (3) EP1056845B1 (pt)
JP (1) JP2002504326A (pt)
KR (1) KR20010041111A (pt)
AR (1) AR019818A1 (pt)
AT (2) ATE352619T1 (pt)
AU (1) AU765014B2 (pt)
BR (1) BR9907995A (pt)
CA (2) CA2323607C (pt)
CY (2) CY1108074T1 (pt)
DE (2) DE69934970T2 (pt)
DK (2) DK1770162T3 (pt)
ES (3) ES2280115T3 (pt)
IL (1) IL137831A0 (pt)
NZ (1) NZ506911A (pt)
PT (2) PT1056845E (pt)
WO (1) WO1999042573A1 (pt)
ZA (1) ZA991369B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
MXPA01007366A (es) * 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
TR200400621T2 (tr) 1999-07-20 2004-08-23 Pharmexa A/S GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
US6617440B1 (en) 1999-07-30 2003-09-09 Pfizer, Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
US7368534B2 (en) 2000-01-18 2008-05-06 Orico Limited Myostatin and mimetics thereof
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP1699820A2 (en) * 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
EP1799709B1 (en) * 2004-09-30 2012-04-04 ORICO Limited Myostatin isoform
CA2594276A1 (en) * 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
CN101522707B (zh) * 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
BRPI0716249A2 (pt) 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
CN104391628B (zh) * 2014-04-02 2018-02-23 贵阳朗玛信息技术股份有限公司 进程切换方法及装置
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP7445640B2 (ja) * 2019-03-01 2024-03-07 神戸天然物化学株式会社 ミオスタチンスプライスバリアント由来タンパク質によるミオスタチンシグナル阻害とその利用
WO2025192635A1 (ja) * 2024-03-12 2025-09-18 リージョナルフィッシュ株式会社 魚類の肉質を改善する方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1605763A (en) 1926-11-02 Garment retainer
US2754818A (en) 1950-06-24 1956-07-17 Scherer Corp R P Hypo jet injector
US3330276A (en) 1963-10-07 1967-07-11 Scherer Corp R P Hypodermic jet injector
US3788315A (en) 1971-04-20 1974-01-29 S Laurens Disposable cutaneous transjector
US3853125A (en) 1971-10-05 1974-12-10 W Clark Disposable needleless injector
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 ２気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4518385A (en) 1983-06-13 1985-05-21 Preci-Tech Ltd. Disposable syringe for needleless injector
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5062830A (en) 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP1574577A3 (en) 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
AU756620B2 (en) 1997-07-14 2003-01-16 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
TR200400621T2 (tr) 1999-07-20 2004-08-23 Pharmexa A/S GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Also Published As

Publication number Publication date
WO1999042573A1 (en) 1999-08-26
NZ506911A (en) 2003-09-26
PT1056845E (pt) 2007-04-30
DK1770162T3 (da) 2009-04-14
AU2507399A (en) 1999-09-06
AU765014B2 (en) 2003-09-04
DE69934970T2 (de) 2007-10-25
CA2687533A1 (en) 1999-08-26
ATE352619T1 (de) 2007-02-15
DE69940230D1 (de) 2009-02-12
EP2018871A1 (en) 2009-01-28
AR019818A1 (es) 2002-03-20
CY1108889T1 (el) 2014-07-02
EP1770162B1 (en) 2008-12-31
DE69934970D1 (de) 2007-03-15
CA2323607A1 (en) 1999-08-26
EP1056845B1 (en) 2007-01-24
EP1770162A1 (en) 2007-04-04
KR20010041111A (ko) 2001-05-15
CA2687533C (en) 2016-02-02
ATE419353T1 (de) 2009-01-15
IL137831A0 (en) 2001-10-31
CY1108074T1 (el) 2014-02-12
ZA991369B (en) 1999-08-20
US6369201B1 (en) 2002-04-09
ES2318654T3 (es) 2009-05-01
ES2527410T3 (es) 2015-01-23
CA2323607C (en) 2009-12-22
EP1056845A1 (en) 2000-12-06
EP2018871B1 (en) 2014-10-08
DK1056845T3 (da) 2007-05-29
JP2002504326A (ja) 2002-02-12
BR9907995A (pt) 2001-05-15
ES2280115T3 (es) 2007-09-01
US20030065137A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
PT1770162E (pt) Composições imunológicas para a modulação da miostatina em indivíduos vertebrados
GB2335545B (en) Improvements in or relating to enclosures
HUP0103388A3 (en) Oral liquid mucoadhesive compositions
GB9817457D0 (en) Improvements in or related to organic compositions
HUP0004001A2 (en) Oil in water vaccine compositions
GB9604849D0 (en) Improvements in or relating to organic compositions
GB9703498D0 (en) Improvements in or relating to organic compositions
GB9812455D0 (en) Improvements in or relating to organic compositions
GB9604883D0 (en) Improvements in or relating to organic compositions
HU9800876D0 (en) Liquid antacid compositions
GB9707212D0 (en) Improvements in or related to organic compositions
IL115442A0 (en) Liquid antacid compositions
GB2334721B (en) Cleansing composition
ZA987370B (en) Cleansing compositions
ZA987367B (en) Cleansing compositions
PL331478A1 (en) Application of oligosaccharide as immunomodulator in dermatocosmetic compositions
EP0731142A3 (en) Thixotropic organopolysiloxane compositions
GB9613901D0 (en) Cleansing compositions
GB9613968D0 (en) Cleansing compositions
GB9613944D0 (en) Cleansing compositions
GB9722013D0 (en) Cleansing compositions
GB9622844D0 (en) Cleansing compositions
GB9604884D0 (en) Improvements in or relating to organic compositions
GB9721373D0 (en) Improvements in liquid compositions
ZA987366B (en) Cleansing compositions